| Attribute |
Value |
| 52 Week Change |
0.1288538 |
| Address1 |
101 South Street |
| Address2 |
Suite 900 |
| All Time High |
18.18 |
| All Time Low |
11.0 |
| Ask |
18.3 |
| Ask Size |
2 |
| Average Daily Volume10 Day |
952,290 |
| Average Daily Volume3 Month |
786,672 |
| Average Volume |
786,672 |
| Average Volume10Days |
952,290 |
| Bid |
10.3 |
| Bid Size |
2 |
| Book Value |
4.016 |
| City |
Somerville |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
14.3599 |
| Current Ratio |
9.169 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
14.43 |
| Day Low |
14.07 |
| Debt To Equity |
12.737 |
| Display Name |
Generate Biomedicines |
| Earnings Timestamp |
1,778,157,000 |
| Earnings Timestamp End |
1,786,019,400 |
| Earnings Timestamp Start |
1,786,019,400 |
| Ebitda |
-238,086,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-5.794 |
| Enterprise To Revenue |
45.53 |
| Enterprise Value |
1,379,517,696 |
| Eps Current Year |
-2.24 |
| Eps Forward |
-2.065 |
| Eps Trailing Twelve Months |
-2.07 |
| Esg Populated |
0 |
| Exchange |
NMS |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
14.4398 |
| Fifty Day Average Change |
-0.07989979 |
| Fifty Day Average Change Percent |
-0.0055333027 |
| Fifty Two Week Change Percent |
12.88538 |
| Fifty Two Week High |
18.18 |
| Fifty Two Week High Change |
-3.8200998 |
| Fifty Two Week High Change Percent |
-0.2101265 |
| Fifty Two Week Low |
11.0 |
| Fifty Two Week Low Change |
3.3599005 |
| Fifty Two Week Low Change Percent |
0.3054455 |
| Fifty Two Week Range |
11.0 - 18.18 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,772,202,600,000 |
| Float Shares |
60,287,643 |
| Forward Eps |
-2.065 |
| Forward P E |
-6.9539466 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
312 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Gross Profits |
-205,386,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.14068 |
| Held Percent Institutions |
0.72915 |
| Implied Shares Outstanding |
128,192,484 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,026-02-27 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts. |
| Long Name |
Generate Biomedicines, Inc. |
| Market |
us_market |
| Market Cap |
1,840,831,232 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_659065371 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-265,440,992 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
1,830,588,671 |
| Number Of Analyst Opinions |
5 |
| Open |
14.4 |
| Operating Cashflow |
-227,831,008 |
| Operating Margins |
-8.87486 |
| Payout Ratio |
0.0 |
| Phone |
(888) 469-0055 |
| Previous Close |
14.28 |
| Price Eps Current Year |
-6.41067 |
| Price Hint |
2 |
| Price To Book |
3.5756726 |
| Price To Sales Trailing12 Months |
60.755512 |
| Profit Margins |
0.0 |
| Quick Ratio |
8.848 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
0.07990074 |
| Regular Market Change Percent |
0.559529 |
| Regular Market Day High |
14.43 |
| Regular Market Day Low |
14.07 |
| Regular Market Day Range |
14.07 - 14.43 |
| Regular Market Open |
14.4 |
| Regular Market Previous Close |
14.28 |
| Regular Market Price |
14.3599 |
| Regular Market Time |
1,784,037,404 |
| Regular Market Volume |
31,651 |
| Revenue Growth |
-0.181 |
| Revenue Per Share |
0.521 |
| Sand P52 Week Change |
0.20365608 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
128,192,484 |
| Shares Percent Shares Out |
0.0462 |
| Shares Short |
5,916,840 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
4,087,393 |
| Short Name |
Generate Biomedicines, Inc. |
| Short Percent Of Float |
0.0793 |
| Short Ratio |
4.93 |
| Source Interval |
15 |
| State |
MA |
| Symbol |
GENB |
| Target High Price |
30.0 |
| Target Low Price |
22.0 |
| Target Mean Price |
25.4 |
| Target Median Price |
25.0 |
| Total Cash |
516,640,992 |
| Total Cash Per Share |
4.03 |
| Total Debt |
65,570,000 |
| Total Revenue |
30,299,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-2.07 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
13.47 |
| Two Hundred Day Average Change |
0.8899002 |
| Two Hundred Day Average Change Percent |
0.06606534 |
| Type Disp |
Equity |
| Volume |
31,651 |
| Website |
https://generatebiomedicines.com |
| Zip |
2,143 |